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Dengue	   disease	   is	   caused	   by	   four	   different	   flavivirus1	   serotypes,	   which	  
infect	  390	  million	  people	  yearly	  with	  25%	  symptomatic	  cases2	  and	  for	  which	  no	  
licensed	   vaccine	   is	   available.	   Recent	   phase	   III	   vaccine	   trials	   showed	   partial	  
protection,	   and	   in	   particular	   no	   protection	   for	   dengue	   virus	   serotype	   2	   (DENV-­‐
2)3,4.	   Structural	   studies	   so	   far	   have	   characterized	   only	   epitopes	   recognized	   by	  
serotype	   specific	   human	   antibodies5,6.	   We	   recently	   isolated	   human	   antibodies	  
potently	   neutralizing	   all	   four	   DENV	   serotypes7.	   Here	   we	   describe	   the	   X-­‐ray	  
structures	   of	   four	   of	   these	   broadly	   neutralizing	   antibodies	   (bnAbs)	   in	   complex	  
with	   the	   envelope	   glycoprotein	   E	   from	   DENV-­‐2,	   revealing	   that	   the	   recognition	  
determinants	  are	  at	  a	  serotype	  conserved	  site	  at	  the	  E	  dimer	  interface,	  including	  
the	  exposed	  main	  chain	  of	  the	  E	  fusion	  loop8	  and	  the	  two	  conserved	  glycan	  chains.	  
This	   “E-­‐dimer	   dependent	   epitope”	   (EDE)	   is	   also	   the	   binding	   site	   for	   the	   viral	  
glycoprotein	   prM	   during	   virus	   maturation	   in	   the	   secretory	   pathway	   of	   the	  
infected	   cell9,	   explaining	   its	   conservation	   across	   serotypes	   and	   highlighting	   an	  
Achilles	  heel	  of	  the	  virus	  with	  respect	  to	  antibody	  neutralization.	  	  These	  findings	  
will	   be	   instrumental	   for	   devising	   novel	   immunogens	   to	   protect	   simultaneously	  
against	  all	  four	  serotypes	  of	  dengue	  virus.	  
Exposed	  at	  the	  surface	  of	  infectious	  mature	  DENV	  particles,	  protein	  E	  is	  the	  sole	  target	  of	  neutralizing	  antibodies.	  It	  displays	  an	  icosahedral	  arrangement	  in	  which	  90	  E	  dimers	  completely	  coat	  the	  viral	  surface10,11	  and	  which	  is	  sensitive	  to	  the	  environmental	  pH.	   Upon	   entry	   of	   DENV	   into	   cells	   via	   receptor-­‐mediated	   endocytosis,	   the	   acidic	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endosomal	  environment	  triggers	  an	   irreversible	   fusogenic	  conformational	  change	   in	  E	  that	  leads	  to	  fusion	  of	  viral	  and	  endosomal	  membranes1.	  The	  structure	  of	  the	  isolated	  E	  dimer	   has	   been	   determined	   by	   X-­‐ray	   crystallography	   using	   the	   soluble	   ectodomain	  (sE)8,12.	   Protein	  E	   is	   relatively	   conserved,	   displaying	   about	  65%	  amino	   acid	   sequence	  identity	  when	  comparing	  the	  most	  distant	  DENV	  serotypes.	  In	  particular,	  there	  are	  two	  conserved	   N-­‐linked	   glycosylation	   sites	   at	   positions	   N67	   and	   N153.	   To	   examine	   its	  interaction	  with	  the	  antibodies,	  we	  selected	  four	  highly	  potent	  bnAbs	  identified	   in	  the	  accompanying	  work:	  747(4)	  A11	  and	  747	  B7	   (EDE2	  group,	   requiring	  glycosylation	  at	  position	  N153	  for	  efficient	  binding)	  and	  752-­‐2	  C8	  and	  753(3)	  C10	  (EDE1	  group,	  binding	  regardless	   of	   the	   glycosylation	   at	   N153)7	   –	   referred	   to	   as	   A11,	   B7,	   C8	   and	   C10	   from	  hereon.	   The	  EDE2	  bnAbs	  were	   isolated	   from	   the	   same	  patient	   (who	  had	   a	   secondary	  infection	  with	  DENV-­‐2),	  and	  are	  somatic	  variants	  of	   the	  same	   IgG	  clone,	  derived	   from	  the	  IGHV3-­‐74	  and	  IGLV2-­‐23	  germ	  lines.	  The	  heavy	  chain	  has	  a	  very	  long	  (26	  amino	  acids,	  IMGT	  convention)	  complementarity-­‐determining	  region	  3	   (CDR	  H3).	  The	  EDE1	  bnAbs	  were	   isolated	   from	  different	  patients	  and	  derive	   from	  VH	  and	  VL	  genes	   IGHV3-­‐64	  and	  
IGKV3-­‐11,	  (EDE1	  C8,	  the	  patient	  appeared	  to	  have	  a	  primary	  infection	  of	  undetermined	  serotype)	  and	  IGHV1-­‐3*	  and	  IGLV2-­‐14	  (EDE1	  C10,	  from	  a	  patient	  with	  secondary	  DENV-­‐1	   infection).	   The	   analysis	   of	   the	   genes	   coding	   for	   these	   antibodies	   is	   summarized	   in	  Table	  1.	  	  
Recombinant	  sE	  is	  mainly	  monomeric	  in	  solution,	  but	  crystallizes	  as	  dimer	  8,12,13.	  	  The	   crystal	   structures	   of	   the	   antibody/antigen	   complexes	   were	   determined	   as	  described	   in	   the	   Methods	   section,	   to	   a	   resolution	   between	   3.0Å	   and	   3.2Å	   for	   the	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complexes	  with	  B7,	  C10	  and	  C8;	  and	  3.85Å	  for	  the	  complex	  with	  A11	  (ED	  Table	  1).	  They	  show	  that	  all	   four	  bnAbs	  bind	  in	  a	  similar	  way	  (Fig.	  1),	   interacting	  with	  both	  subunits	  and	  leaving	  a	  similar	  footprint	  on	  the	  sE	  dimer	  (ED	  Figure	  1).	  	  
The	  antibody/antigen	  contacts	  are	  centered	  in	  a	  valley	  lined	  by	  the	  b	  strand	  on	  the	   domain	   II	   side,	   and	  by	   the	   “150	   loop”	   of	   domain	   I	   of	   the	   adjacent	   subunit	   on	   the	  opposite	   side	   (Fig	   1d),	   with	   the	   heavy	   chain	   contacting	   both	   N67	   and	   N153	   glycans	  across	   the	   E	   dimer	   interface	   (Fig	   1e-­‐g).	   	   The	   150	   loop	   spans	   residues	   148-­‐159,	  connecting	   β-­‐strands	   E0	   and	   F0	   of	   domain	   I14,	   and	   carries	   the	  N153	   glycan.	   The	   total	  buried	   surface	   area	   (BSA)	  per	  epitope	   ranges	  between	  1050	  Å2	   and	  1400	  Å2,	   and	   the	  surface	  complementarity	  coefficient15	  is	  between	  0.67	  and	  0.74	  (ED	  Table	  2),	  which	  are	  values	   typical	   for	   antibody/antigen	   complexes.	   The	   surface	   electrostatic	   potentials	   of	  epitope	  and	  paratopes	  are	  mildly	  charged	  (ED	  Fig.	  2),	  with	  a	  relatively	  complementary	  charge	  distribution.	  The	  EDE2	  antibodies	  recognize	  sE	  essentially	  via	  the	  heavy	  chain,	  with	   the	   light	   chain	   involved	  only	   in	   contacts	  with	   the	  N153	   glycan.	  The	  heavy	   chain	  buries	  nearly	  85%	  of	   the	   total	  BSA	   -­‐	  63%	  belonging	   to	   the	   long	  EDE2	  CDR	  H3,	  which	  forms	  a	  protrusion	  matching	  the	  concave	  surface	  of	  the	  sE	  dimer.	  This	  protrusion	  is	  pre-­‐formed	   in	   the	  antibody,	   as	   shown	  by	   the	  1.7	  Å	   resolution	  structure	  of	   the	  unliganded	  EDE2	  A11	  scFv	  (ED	  Fig.	  3),	  indicating	  no	  entropic	  cost	  for	  binding.	  In	  contrast,	  the	  EDE1	  antibodies	   engage	   a	   substantial	   amount	   of	   light	   chain	   contacts	   from	   all	   3	   CDR	   and	  framework	  (FRW)	  regions,	  contributing	  in	  total	  40%	  in	  C8	  and	  47%	  in	  C10	  of	  the	  BSA	  in	  the	  complex	  with	  sE.	  Although	   the	  germlines	  are	  different	  between	  EDE1	  C8	  and	  C10	  and	  the	  CDRs	  contribute	  differently	  to	  the	  paratope	  (Fig.	  2a),	  the	  chemical	  nature	  of	  the	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residues	   involved	   is	   similar,	   including	   a	   clear	   clustering	   of	   aromatic	   side	   chains	   -­‐	   a	  feature	  shared	  with	  the	  EDE2	  bnAbs	  (Fig.	  2b).	  
The	  bnAb	   contacts	   cluster	  on	   residues	  at	   the	  dimer	   interface	   (Fig.	   1c)	   that	   are	  conserved	  across	   the	   four	   serotypes	   (ED	  Fig.	  4a),	   explaining	   their	   cross-­‐reactivity.	  On	  domain	   II,	   both	   EDE1	   and	   EDE2	   bnAbs	   target	   the	   same	   residues	   (ED	   Figs.	   4	   and	   5),	  which	  map	  to	  three	  main	  polypeptide	  segments:	  the	  b	  strand	  (aa	  67-­‐74,	  bearing	  the	  N67	  glycan),	  the	  fusion	  loop	  and	  residues	  immediately	  upstream	  (aa	  97-­‐106),	  and	  the	  ij	  loop	  (aa	  246-­‐249).	   In	  contrast,	  on	   the	  opposite	  subunit	   the	  residues	   targeted	  are	  different:	  the	  EDE2	  bnAbs	  interact	  with	  the	  150	  loop	  and	  the	  N153	  glycan	  chain,	  whereas	  EDE1	  bnAbs	   target	   domain	   I	   and	   III	   and	   induce	   disorder	   of	   the	   150	   loop.	   The	   structure	   of	  unliganded	  DENV-­‐2	   sE	  of	   the	   same	   strain	   (FGA-­‐02,	   Fig.	   1b-­‐d),	   determined	   in	  parallel,	  was	  useful	  in	  assessing	  that	  EDE1	  antibody	  binding	  indeed	  displaces	  the	  150	  loop.	  This	  is	  relevant	  because	  a	  previous	  structure	  of	  DENV-­‐4	  sE	  in	  complex	  with	  an	  antibody	  that	  binds	  away	  from	  the	  EDE	  also	  had	  the	  150	  loop	  disordered13,	  highlighting	  an	  intrinsic	  mobility	  in	  this	  area	  depending	  on	  the	  E	  amino	  acid	  sequence.	  Displacement	  of	  the	  150	  loop	   allows	   the	   EDE1	   light	   chain	   to	   come	   closer	   to	   sE	   and	   interact	   with	   domain	   III	  (compare	  panel	  e	  with	  f	  and	  g	  in	  Fig.1)	  in	  the	  region	  of	  the	  “A	  strand”	  epitope,	  which	  has	  been	   structurally	   characterized	   previously	   for	   murine	   DENV	   cross-­‐reactive	  antibodies16,17.	   These	   domain	   III	   contacts	   are	   centered	   on	   the	   conserved	   E	   residue	  K310,	  the	  side	  chain	  of	  which	  makes	  a	  lid	  covering	  the	  indole	  ring	  of	  W101	  of	  the	  fusion	  loop	  (ED	  Fig.	  6a),	  in	  an	  important	  stabilizing	  E	  dimer	  contact.	  	  
	   6	  
The	  bnAbs	  make	  extensive	  interactions	  with	  the	  glycan	  chains,	  both	  at	  positions	  N67	  and	  N153	  of	  E	  (ED	  Figs.	  6	  and	  7),	  using	  opposite	  sides	  of	  the	  paratope	  (Fig.	  2a).	  sE	  in	  complex	  with	  EDE1	  C8	  displays	  the	  highest	  ordered	  N67	  glycan	  structure	  (ED	  Fig.	  7),	  with	   interactions	   with	   CDR	   H2	   (Fig.	   2a).	   The	   distant	   mannose	   residues	   contact	   the	  framework	  region	  3	  (FRW	  H3,	  ED	  Figs.	  4b	  and	  7).	  Except	  for	  EDE1	  C10	  (which	  is	  very	  close	   to	   its	  germ	  line,	  Table	  1),	  several	  FRW	  H3	  residues	   in	   the	  other	  bnAbs	  analyzed	  have	  undergone	   changes	   (ED	  Fig.	   4b),	   suggesting	   affinity	  maturation	   to	   recognize	   the	  sugars.	  With	  respect	  to	  the	  N153	  glycan,	  the	  electron	  density	  is	  clear	  for	  its	  core	  6	  sugar	  residues	  in	  the	  structure	  of	  sE	  in	  complex	  with	  the	  EDE2	  bnAbs	  (including	  in	  omit	  maps,	  as	   shown	   in	  ED	  Fig.	  7).	  A	   short	  α-­‐helix	   in	  A11	  and	  B7	  CDR	  H3	  projects	  aromatic	   side	  chains	   that	   pack	   against	   the	   sugar	   residues	   1,	   3	   and	   4	   of	   the	  N153	   glycan.	   The	  most	  distant	  residues	  of	  the	  glycan,	  mannoses	  4,	  5	  and	  6,	  are	  in	  contact	  with	  the	  light	  chain,	  via	  residues	  from	  CDR	  L2,	  including	  several	  hydrogen	  bonds	  (ED	  Fig.	  7	  and	  SI)	  
The	   glycine	   rich	   fusion	   loop	   in	   the	   E	   dimer	   is	   such	   that	   it	   essentially	   exposes	  main	  chain	  atoms,	  while	  the	  hydrophobic	  side	  chains	  are	  mostly	  buried.	  Together	  with	  the	   main	   chain	   of	   the	   ij	   loop,	   main	   chain	   atoms	   make	   a	   large	   surface	   patch	   that	   is	  augmented	  by	  the	  exposed	  edge	  of	  the	  b	  strand	  (Fig.	  3).	  The	  bnAbs	  make	  a	  number	  of	  specific	  hydrogen	  bonds	  to	  the	  sE	  main	  chain,	  (ED	  Fig.	  6,	  see	  also	  list	  of	  interactions	  in	  SI).	  Furthermore,	  the	  exposed	  side	  chains	  in	  this	  area	  are	  mostly	  conserved,	  resulting	  in	  a	   core	   region	   of	   the	   EDE	   that	   is	   serotype	   invariant,	   with	   non-­‐conserved	   residues	  essentially	  at	  the	  periphery.	  The	  principal	  binding	  determinants	  of	  the	  EDE	  bnAbs	  thus	  appear	   to	  be	  the	  conformation	  of	   the	  main	  chain	  of	   the	   fusion	   loop	  and	   its	   immediate	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neighbors	  in	  the	  context	  of	  an	  intact	  E	  dimer.	  This	  contrasts	  with	  the	  other	  major	  class	  of	   antibodies	   isolated	   from	   humans,	   which	   recognize	   the	   fusion	   loop	   sequence	   in	   a	  context	   independent	  of	   the	  quaternary	  organization7.	  The	   latter	  are	  cross	  reactive	  but	  poorly	  neutralizing	  and	  have	  a	  strong	  infection	  enhancing	  potential18.	  	  
What	   is	   the	  reason	  for	  the	  strong	  conservation	  of	   this	  site	  across	  serotypes?	  In	  the	   infected	   cell,	   newly	   synthesized	   immature	   DENV	   virions	   bud	   into	   the	   ER	   lumen,	  where	  the	  pH	  is	  neutral.	  These	  particles	  contain	  180	  copies	  of	  a	  heterodimer	  of	  E	  with	  the	   precursor	   membrane	   glycoprotein	   prM	   at	   their	   surface19,20.	   As	   they	   are	  subsequently	  transported	  to	  the	  external	  medium	  across	  the	  Golgi	  apparatus,	  where	  the	  pH	   is	   acidic,	   the	   interaction	  with	   prM	   protects	   E	   from	   undergoing	   a	   premature	   acid-­‐induced	   fusogenic	   conformational	   change1.	   The	   E/prM	   heterodimers	   reversibly	  associate	   as	   60	   trimers	   or	   90	   dimers	   at	   neutral	   or	   acidic	   pH,	   respectively9,21.	   Upon	  cleavage	  of	  its	  viral	  membrane	  tether	  by	  the	  TGN	  resident	  furin	  protease,	  prM	  remains	  bound	   to	   E	   dimers	   as	   long	   as	   the	   environment	   is	   acidic	   but	   it	   is	   released	   when	   the	  particle	  reaches	  the	  exterior	  of	  the	  cell	  (where	  the	  pH	  is	  neutral),	  thereby	  activating	  the	  virion	  to	  become	  fusogenic	  upon	  re-­‐encountering	  the	  acidic	  endosomal	  environment	  of	  a	  new	  cell.	  The	  binding	  site	  of	  prM	  on	  the	  E	  dimer9,21	  maps	  precisely	  to	  the	  EDE	  (Fig.	  3),	  explaining	   its	   high	   conservation.	   	   As	   the	   E	   dimer	   conformation	  with	   bound	   prM	  was	  observed	  on	  immature	  particles	  at	   low	  pH	  only9,	  at	  neutral	  pH	  the	  EDE	  is	  not	  formed,	  and	   accordingly	   bnAbs	   do	   not	   bind	   to	   particles	   that	   are	   100%	   immature7,	  which	   are	  formed	   exclusively	   of	   E/prM	   trimers19.	   But	   the	   efficient	   binding	   of	   the	   bnAbs	   to	  particles	  that	  have	  more	  than	  60	  %	  uncleaved	  prM7,	  which	  have	  been	  shown	  to	  display	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patches	  of	  immature	  E/prM	  trimers	  at	  their	  surface22,23,	  shows	  that	  these	  trimers	  must	  undergo	   a	   dynamic	   exchange	   with	   dimers.	   As	   the	   bnAbs	   have	   a	   higher	   affinity	   they	  outcompete	   uncleaved	   prM	   on	   partially	   immature	   virions	   from	   its	   interaction	  with	   E	  dimers,	   binding	   by	   conformational	   selection24.	   This	   process	   effectively	   displaces	   the	  equilibrium	  toward	  dimers,	  similar	  to	  the	  bnAb-­‐induced	  shift	  toward	  dimers	  of	  the	  sE	  monomer-­‐dimer	  equilibrium	  in	  solution	  (data	  not	  shown).	  Because	   the	  degree	  of	  prM	  cleavage	  is	  variable	  and	  depends	  on	  the	  particular	  cell	  in	  which	  the	  virus	  was	  replicated,	  the	   fact	   that	   these	   bnAbs	   bind	   efficiently	   partially	  mature	   particles	   is	   expected	   to	   be	  important	  for	  protection	  in	  humans.	  	  
The	  EDE	  is	  totally	  circumscribed	  to	  the	  E	  dimer	  and	  therefore	  it	  does	  not	  depend	  on	  the	  higher	  order	  arrangement	  of	  dimers,	  as	  recently	  suggested	  for	  other	  quaternary	  epitopes	  on	  the	  DENV	  particle25	  based	  on	  studies	  on	  a	  different	  flavivirus,	  the	  West	  Nile	  virus26.	   Recent	   studies	   on	   DENV-­‐2	   detected	   a	   particle	   expansion	   at	   physiological	  temperatures	  of	  humans,	   causing	   the	  E	  dimers	   to	   reorient	  with	   respect	   to	   each	  other	  and	   presenting	   a	   different	   surface	   pattern	   as	   in	   mosquito	   grown	   viruses27,28.	   bnAbs	  targeting	   the	   EDE	  will	   neutralize	   regardless	   of	   the	   surface	   arrangement	   of	   E	   dimers.	  These	  results	  are	  in	  line	  with	  a	  recent	  study	  on	  the	  tick-­‐borne	  encephalitis	  flavivirus,	  in	  which	  the	  corresponding	  recombinant	  sE	  dimer	  efficiently	  depleted	  human	  serum	  from	  neutralizing	  activity29.	  	  
As	  a	  corollary,	  our	  results	  suggest	  that,	  similar	  to	  vaccine	  approaches	  against	  the	  respiratory	   syncytial	   virus30,	   a	   viable	   strategy	   would	   consist	   in	   presenting	   a	   single	  stabilized	   pre-­‐fusion	   E	   dimer	   to	   the	   immune	   system,	   designed	   to	   focus	   the	   B-­‐cell	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response	   on	   the	   EDE,	   instead	   of	   the	   multivalent	   vaccines	   that	   are	   currently	   under	  development.	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FIGURE	  LEGENDS	  
Figure	  1.	  DENV-­‐2	  sE	  in	  complex	  with	  four	  EDE	  bnAbs.	  	  
a)	  Complex	  with	  Fab	  EDE2	  A11.	  The	  sE	  dimer	  is	  in	  surface	  representation	  in	  side	  view,	   with	   the	   viral	   membrane-­‐facing	   side	   below,	   colored	   according	   to	   domains	   as	  labeled,	   with	   foreground	   and	   background	   subunits	   in	   bright	   and	   pale	   colors,	  respectively.	  The	  two	  N-­‐linked	  glycan	  chains	  at	  N67	  and	  N153	  are	  shown	  as	  ball-­‐and-­‐stick	  and	  labeled.	  The	  A11	  Fab	  is	  shown	  as	  ribbon	  with	  heavy	  and	  light	  chains	  in	  green	  and	  grey,	  respectively.	  	  
b)	  The	  unliganded	  DENV2	  FGA02	   sE	  dimer	   seen	  down	   the	  2-­‐fold	   axis	   (labeled	  “2”).	  Green	  and	  grey	  empty	  ovals	  (labeled	  VH	  and	  VL)	  show	  roughly	  the	  contact	  sites	  of	  heavy	  and	  light	  chains,	  respectively.	  Polypeptide	  segments	  relevant	  to	  the	  description	  of	  the	  epitopes	  are	  labeled.	  	  
c)	   	   “Worm”	   representation	   of	   the	   sE	   dimer,	  with	   the	   two	   subunits	   in	   different	  greys.	  Polypeptide	  segments	  in	  contact	  with	  the	  antibodies	  (either	  EDE1	  or	  EDE2)	  are	  shown	  thicker,	  with	  the	  main	  segments	  of	  the	  epitope	  color	  coded	  as	  boxed	  in	  ED	  Fig.	  4a,	  with	  additional	   contact	  segments	   in	  white	  or	  dark	  grey,	  depending	  on	   the	  subunit	  background.	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d)	   View	   down	   the	   empty	   arrow	   shown	   in	   (b),	   highlighting	   the	   fusion	   loop	  “valley”	  encased	  between	  two	  ridges,	  the	  b	  strand	  on	  one	  subunit	  and	  the	  150	  loop	  on	  the	   other.	   e-­‐g)	   same	   view	   as	   in	   (d)	   showing	   the	   complexes	  with	   bnAbs	   EDE2	  B7	   (e),	  EDE1	  C8	  (f)	  and	  EDE1	  C10	  (g)	  (only	  variable	  domains	  are	  shown).	  A	  black	  asterisk	  in	  (f)	  and	  (g)	  marks	  the	  region	  of	  the	  150	  loop,	  disordered	  in	  those	  complexes.	  Note	  that	   in	  the	  B7	  and	  A11	  complexes,	  the	  light	  chain	  is	  too	  far	  up	  to	  reach	  domain	  III.	  
Figure	  2.	  Comparison	  of	  paratopes.	  
a)	   The	   paratopes	   (outlined	   in	   green)	   on	   the	   antibody	   surface	   color-­‐coded	   by	  CDRs.	  The	  oval	  marks	  the	  region	  in	  contact	  with	  the	  E	  fusion	  loop.	  Note	  that	  the	  patch	  interacting	   with	   the	   N153	   glycan	   (labeled)	   in	   EDE2	   bnAbs	   corresponds	   to	   that	  interacting	  with	  domain	  III	  in	  EDE1	  bnAbs.	  
b)	  Chemical	  nature	  of	  paratope	  side	  chains.	  The	  left	  column	  corresponds	  to	  the	  same	   orientation	   as	   in	   a),	   with	   the	   surface	   colored	   according	   to	   the	   side	   chain	   type.	  Exposed	  main	  chain	  atoms	  of	  heavy	  and	  light	  chain	  are	  in	  sand	  and	  white,	  respectively.	  The	   bottom	   panel	   shows	   the	   sE	   dimer	   in	   the	   same	   rendering	   in	   an	   “open	   book”	  orientation	  with	   respect	   to	   the	   antibodies.	   The	   epitope	   area	   is	   indicated	  with	   a	   black	  ellipse,	  with	  the	  fusion	  loop	  within	  the	  magenta	  oval	  corresponding	  to	  the	  one	  drawn	  on	  the	  antibodies.	  
Figure	  3.	  Exposed	  main	  chain	  atoms	  in	  the	  epitope.	  
Surface	  representation	  of	  DENV-­‐2	  sE	  as	  viewed	   from	  outside	   the	  virion,	  with	  exposed	  main	  chain	  atoms	  orange	  (top	  panel)	  or	  with	  main	  chain	  atoms	  +	  conserved	  side	  chains	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in	  orange,	  and	  highly	  similar	  side	  chains	  in	  yellow	  (bottom	  panel).	  The	  epitopes	  of	  EDE1	  bnAb	  C10	  (black	  outline)	  and	  EDE2	  bnAb	  B7	  (green	  outline)	  are	  indicated,	  with	  the	  prM	  footprint	  outlined	  in	  blue.	  
Captions	  to	  Extended	  Data	  Figures.	  	  
ED	  Table	  1.	  Crystallization	  conditions,	  data	  collection	  and	  refinement	  statistics. 	  DENV-­‐2	  sE:	  Den2_FGA-­‐02	  (GenBank	  entry	  KM087965).	  The	  DENV	  sE	  buffer	  used	  for	  all	  the	  crystallization	  experiments	  was:	  150mM	  NaCl	  and	  15mM	  Tris	  pH	  8.	  Proteins	  were	  crystallized	  at	  18°C.	  One	  crystal	  was	  used	  for	  each	  of	  the	  data	  sets.	  *Protein	   concentration	   was	   estimated	   using	   theoretical	   extinction	   coefficients	   of	   the	  complexes	   (DENV	  sE	  +	  Fab	  or	   scFv).	  OD280nm	  of	   the	  protein	   solution	  was	  measured	  before	  crystallization.	  The	   theoretical	  extinction	  coefficients	   for	   individual	   component	  are:	  DENV-­‐2	  sE-­‐His:	  1.03;	  bnAb	  EDE2	  A11	  ScFv:	  2.08;	  bnAb	  EDE2	  B7	  Fab:	  1.65;	  bnAb	  EDE2	  A11	  Fab:	  1.68;	  bnAb	  EDE1	  C8	  Fab:	  1.52;	  bnAb	  EDE1	  C10	  ScFv:	  2.43	  (see	  Methods	  for	  more	   details).	   Extinction	   coefficients	  were	   calculated	  without	   taking	   into	   account	  carbohydrate	  moieties.	  	  †Highest	  resolution	  shell	  is	  shown	  in	  parenthesis.	  	  ‡low-­‐resolution	  for	  refinements	  was	  truncated	  to	  20Å.	  	  §Ramachandran	  statistics	  were	  calculated	  with	  Molprobity31.	  	  Abbreviations	  used:	  PEG	  MME:	  Poly-­‐ethylene	  glycol	  monomethyl	  ether;	  MPD:	  2-­‐Methyl-­‐2,4-­‐pentanediol;	   ND:	   non-­‐determined;	   MR:	   molecular	   replacement;	   NCS:	   non-­‐
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crystallographic	   symetry;	   TLS:	   parametrization	   describing	   translation,	   libration	   and	  screw-­‐rotation	  to	  model	  anisotropic	  displacements.	  
	  
ED	  Table	  2.	  Buried	  accessible	  surface	  areas	  and	  surface	  complementarity	  in	  the	  
various	  DENV	  sE	  -­‐	  EDE	  complexes. 	  BSA:	   Buried	   Surface	   Area	   (Å2)	   of	   sE	   protein	   by	   the	   Fabs	   or	   ScFv	   (calculated	   with	  program	  'areaimol'	  in	  CCP4).	  SC:	  Shape	  Complementarity	  coefficient	  (calculated	  with	  program	  'sc'	  in	  CCP4).	  
*	  Glycan	  chain	  contribution	  to	  BSA	  in	  Å2	  and	  (%).	  
†	  Main	  chain	  atoms	  contribution	  to	  BSA	  in	  Å2	  and	  (%).	  
‡	  There	  are	  two	  sE	  dimer-­‐(bnAb	  C10	  ScFv)2	  complexes	  in	  the	  asymmetric	  unit.	  
	  
ED	  Fig.	  1.	  Overall	  complexes	  and	  footprint	  of	  the	  bnAbs	  on	  the	  sE	  dimer.	  	  
Each	  row	  corresponds	  to	  a	  different	  sE/bnAbs	  complex	  (except	  for	  the	  first	  one	  which	  shows	   the	   unliganded	   sE	   dimer)	   and	   each	   column	   displays	   the	   same	   orientation,	   as	  labeled.	   In	   the	   first	   two	   columns	   the	   sE	   dimer	   is	   depicted	   as	   ribbons	   and	   the	   bnAb	  variable	  domains	  as	  surface	  colored	  as	  in	  Fig.1.	  In	  the	  side	  view	  (left	  column)	  the	  viral	  membrane	   would	   be	   underneath,	   whereas	   the	   bottom	   view	   (middle	   column)	  corresponds	  to	  the	  sE	  dimer	  seen	  from	  the	  viral	  membrane	  with	  the	  antibodies	  visible	  across	  the	  sE	  ribbons.	  The	  top	  view	  (right	  column)	  shows	  the	  sE	  surface	  as	  presented	  to	  the	  immune	  system	  on	  the	  viral	  particle,	  showing	  the	  footprint	  of	  the	  antibodies	  (green)	  with	  a	  white	  depth-­‐cuing	  fog.	  For	  clarity,	  a	  white	  outline	  delimits	  the	  green	  footprint	  on	  the	   blue	   surface	   of	   domain	   III.	   As	   a	   guide,	   in	   the	   top-­‐left	   panel	   the	   glycan	   chains	   of	  
	   16	  
foreground	   and	   background	   subunits	   are	   labeled	   in	   red	   and	   black	   respectively.	   The	  fusion	  loop	  and	  the	  ij	  loop	  are	  labeled	  on	  the	  top-­‐middle	  panel,	  and	  can	  be	  seen	  in	  the	  other	  rows	  in	  contact	  with	  the	  bnAbs.	  A	  red	  star	  in	  the	  left	  panels	  of	  row	  c	  and	  d	  marks	  the	  location	  of	  the	  150	  loop,	  which	  is	  disordered	  in	  the	  complexes	  with	  the	  EDE1	  bnAbs.	  This	   loop	  bears	  the	  N153	  glycan	  recognized	  by	  the	  EDE2	  bnAbs,	  as	  seen	  in	  row	  b,	   left	  panel	  (glycan	  shown	  as	  sticks	  with	  carbon	  atoms	  colored	  red).	  In	  contrast,	  all	  the	  bnAbs	  are	   seen	   contacting	   the	  N67	   glycan,	  with	  C8	  displaying	   the	  most	   contacts	   (row	   c,	   left	  panel,	  N67	   glycan	   as	   sticks	  with	   carbon	   atoms	   yellow).	   A	   blue	   star	   in	   row	   c	   shows	   a	  disordered	   loop	   in	  domain	   III.	  Note	   that	  EDE1	  C10	  (row	  d)	   inserts	  deeper	   into	   the	  sE	  dimer	  than	  the	  others	  bnAbs.	  
	  
	  
ED	  Fig.	  2.	  Electrostatic	  potential	  of	  paratopes	  and	  the	  epitope	  on	  DENV-­‐2.	  	  
Open	   book	   representation	   of	   the	   complexes,	   with	   negative	   and	   positive	   potential	  displayed	   and	   colored	   according	   to	   the	   bar	   underneath.	   Because	   certain	   regions	   are	  disordered	   in	   the	   complexes,	   the	   unliganded	   DENV-­‐2	   sE	   dimer	   model,	   generated	   as	  described	  in	  the	  Online	  Methods	  section,	  was	  used	  to	  calculate	  the	  surface	  electrostatic	  potential	  of	   the	  sE	  dimer.	  Corresponding	  areas	   in	  contact	  are	   indicated	  by	  ovals	  as	   in	  Fig.	  2.	  	  
ED	  Fig.	  3.	  Unliganded	  bnAb	  A11	  and	  EDE2	  bnAbs	  in	  interactions	  with	  DENV-­‐2	  sE.	  	  
a)	  The	  structure	  of	  the	  unliganded	  EDE2	  A11	  scFv	  (red,	  1.7Å	  resolution)	  superposed	  to	  the	  variable	  domain	  of	  Fab	  A11	  in	  complex	  with	  DENV-­‐2	  sE	  (yellow,	  3.8	  Å	  resolution),	  to	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show	  that	  the	  same	  conformation	  is	  retained	  in	  the	  sE/Fab	  fragment	  complex.	  	  b)	  Stereo	  view	  showing	  the	  superposed	  B7	  (green)	  and	  A11	  (yellow)	  variable	  domains,	  together	   with	   the	   150	   loop	   extracted	   from	   the	   structures	   of	   the	   corresponding	  Fab/DENV-­‐2	  sE	  complexes.	  Note	   that	   the	  main	  chain	  of	   the	  150	   loop	  adopts	  different	  conformations	  in	  the	  two	  complexes,	  mainly	  because	  of	  the	  hydroxyl	  group	  the	  Y99	  side	  chain	   in	   the	   CDR	   H3	   of	   B7	   makes	   a	   hydrogen	   bond	   with	   sE	   T155.	   A11	   has	   a	  phenylalanine	  at	   this	  position,	  and	  so	   lacks	   the	  hydroxyl	  group.	  The	  sE	  protein	   in	   the	  complex	  with	  A11	  displays	  the	  same	  conformation	  as	  the	  unliganded	  sE	  (not	  shown).	  	  c)	  Histograms	  of	  the	  atomic	  contacts	  of	  B7	  (above	  the	  sE	  sequence)	  and	  A11	  (below	  the	  sequence).	  	  
	  
ED	  Fig.	  4.	  Residues	  involved	  in	  bnAb/antigen	  interactions.	  	  
a)	  Amino	  acid	  sequence	  alignment	  of	  sE	  from	  the	  four	  DENV	  serotypes,	  with	  residues	  in	  black	  or	  light	  blue	  background	  highlighting	  identity	  and	  similarity,	  respectively,	  across	  serotypes.	   Secondary	   structure	   elements	   are	   indicated	   underneath,	   with	   tertiary	  organization	  given	  by	  colors	  as	  in	  Fig.	  1.	  DENV-­‐2	  sE	  residues	  contacted	  by	  the	  bnAbs	  are	  marked	  above,	  according	   to	   the	  code	  of	   the	  key	   (bottom-­‐right	   insert).	  Full	   and	  empty	  symbols	   correspond	   to	   contacts	   on	   the	   reference	   subunit	   (defined	   as	   the	   one	  contributing	  the	  fusion	  loop	  to	  the	  epitope)	  and	  opposite	  subunit,	  respectively.	  Colored	  boxes	  highlight	   the	  5	  distinct	   regions	  of	   sE	  making	  up	   the	   epitopes,	  matching	  Fig.	   1c.	  The	   histogram	   with	   the	   number	   of	   atomic	   contacts	   per	   sE	   residue	   by	   each	   bnAb	   is	  provided	   as	   Supplementary	   Information.	   Because	   the	   EDE2	   B7	   and	   A11	   contacts	   are	  very	  similar,	  only	  the	  B7	  contacts	  are	  shown	  here.	  The	  question	  mark	  on	  the	  150	  loop	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indicates	   residues	   likely	   to	   contact	   the	   EDE1	   bnAbs,	   but	  which	   are	   not	   visible	   in	   the	  structure	  because	  the	  loop	  is	  disordered.	  
b)	  Sequence	  alignment	  of	  the	  four	  bnAbs	  crystallized,	  (in	  Kabat	  numbering32)	  and	  with	  the	  FRW	  and	  CDR	  regions	   in	  grey	  and	  white	  background,	  respectively.	  Blue	   lines	  over	  the	   sequence	  mark	   the	  CDRs	   in	   the	   IMGT	   convention33.	   Somatic	  mutations	   are	   in	   red	  with	   germline	   residues	   in	   smaller	   font	   underneath.	   Residues	   arising	   from	   the	  recombination	   process	   are	   in	   green.	   A	   symbol	   above	   the	   sequence	   indicates	   the	   sE	  segment	   contacted,	   according	   to	   the	   key	   of	   the	   bottom-­‐right	   inset.	   The	   secondary	  structure	   elements	   of	   the	   EDE2	   C8	   Ig	   β-­‐barrels	   are	   indicated	   above	   the	   sequence,	   as	  guide.	  	  
ED	  Fig.	  5.	  Epitopes	  and	  paratopes.	  
The	  epitope	  area	  of	  DENV-­‐2	  sE	  from	  three	  different	  complexes	   is	  highlighted	   in	  green	  and	  dark	  grey,	  with	  relevant	  side	  chains	  as	  sticks,	  corresponding	  to	  residues	  interacting	  with	   the	   heavy	   and	   light	   chain,	   respectively	   (left	   panels).	   The	   variable	   domain	   of	   the	  corresponding	  bnAb	  is	  shown	  in	  side	  view,	  with	  interacting	  side	  chains	  labeled.	  	  Heavy	  and	  light	  chains	  are	  in	  dark	  and	  light	  grey,	  respectively,	  with	  somatic	  mutations	  in	  red	  and	  residues	  that	  arose	  through	  the	  recombination	  process	  (third	  CDR	  in	  each	  chain)	  in	  green.	  a)	  EDE2	  B7	  complex;	  b)	  EDE1	  C10	  complex;	  c)	  EDE1	  C8	  complex.	  	  
ED	  Fig.	  6.	  Key	  interactions	  of	  the	  bnAbs	  with	  sE	  
a)	  The	  right	  panel	  shows	  the	  sE	  dimer	  in	  ribbons,	  with	  the	  framed	  area	  enlarged	  in	  the	  right	  panel	  to	  show	  the	  epitope,	  with	  main	  features	  labeled.	  b)	  sE	  dimer	  in	  complex	  with	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bnAb	  EDE2	  B7,	  c)	  with	  EDE1	  C8	  and	  d)	  with	  EDE1	  C10.	  The	  sE	  dimer	  surface	  is	  shown	  in	   a	   semi-­‐transparent	   representation	   with	   the	   ribbons	   visible	   through.	   The	   glycan	  residues	  were	  not	  included	  in	  the	  surface,	  and	  are	  displayed	  as	  sticks.	  The	  relevant	  CDR	  loops	   of	   the	   bnAbs	   are	   shown	   as	   ribbons	  with	   side	   chains	   as	   sticks	   on	   top	   of	   the	   sE	  protein,	  colored	  as	  in	  Fig.1.	  The	  orientation	  of	  the	  left	  panel	  in	  rows	  b-­‐d	  corresponds	  to	  the	  enlargement	  of	  row	  a,	  and	  the	  right	  panel	  is	  a	  view	  along	  the	  arrow	  in	  Fig.	  1b	  (main	  text).	  Hydrogen	  bonds	  are	  displayed	  as	  dotted	  lines.	  	  
ED	  Fig.	  7.	  Interactions	  with	  the	  glycan	  chains.	  
Ribbon	  representation	  of	  a)	  the	  EDE2	  A11	  Fab	  and	  b)	  the	  EDE1	  C8	  Fab	  in	  complex	  with	  DENV-­‐2	   sE,	   colored	   as	   in	   Fig.	   1.	   The	   simulated	   annealing	   omit	   maps	   contoured	   at	   1	  sigma	  (cyan)	  or	  0.6	  sigma	  (gold)	  show	  clear	  density	  for	  the	  N153	  (in	  a)	  and	  N67	  glycans	  (in	  a	  and	  b)	  (black	  arrows).	  To	  create	  an	  unbiased	  map,	  all	  glycan	  atoms	  were	  removed	  from	  the	  structures,	  all	  B	  factors	  were	  reset	  to	  20	  Å	  and	  the	  structures	  were	  re-­‐defined	  using	   torsion	   dynamics	   simulated	   annealing.	   Note	   that	   the	   antibody	   spans	   the	   two	  glycans	  across	   the	  dimer	   interface	   (as	  also	   shown	   in	  Fig.	  1).	   c)	  Views	  down	   the	  black	  arrow	  in	  a)	  (left	  panel)	  and	  the	  arrow	  in	  b)	  (right	  panel),	  through	  the	  glycan	  chain.	  The	  key	  to	  the	  sugar	  connectivity	  and	  nomenclature	  is	  framed	  at	  the	  center.	  d)	  Contacts	  of	  the	  sugar	  residues	  with	  the	  antibodies,	  coded	  according	  to	  the	  key.	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Methods	  
Recombinant	  sE	  protein	  production.	  
Recombinant	  DENV-­‐2	  FGA02	  sE	  (1-­‐395)	  was	  cloned	  into	  a	  vector	  pMT/BIP/V5-­‐His	  with	  a	   C-­‐terminal	   His-­‐tag	   and	   produced	   in	  Drosophila	   S2	   cells33,	   performed	   essentially	   as	  described	   earlier	   for	   DENV-­‐4	   sE	   (Den4_Burma/63632/1976)13,	   with	   some	  modifications	   (see	   below).	   Briefly,	   sE	   expression	   was	   driven	   by	   the	   metallothionein	  promoter	   and	   was	   induced	   by	   5µM	   of	   CdCl2	   in	   Insect-­‐XPRESS	   medium	   (Lonza).	   The	  constructs	  had	  a	  Drosophila	  BiP	  signal	  sequence	  fused	  at	  the	  N-­‐terminal	  end	  of	  a	  prM-­‐sE	  construct	  for	  efficient	  translocation	  into	  the	  ER	  of	  the	  transfected	  S2	  cells.	  prM	  was	  present	  N-­‐terminal	  to	  sE,	  as	   in	  the	  DENV	  polyprotein	  precursor,	  with	  the	  N-­‐termini	  of	  prM	   and	   sE	   generated	   by	   signalase	   cleavage	   in	   the	   ER,	   where	   prM	   (which	   remains	  membrane-­‐anchored)	   plays	   a	   chaperone	   role	   by	   masking	   the	   fusion	   loop	   of	   sE.	   The	  prM/sE	  complex	  is	  transported	  across	  the	  acidic	  compartments,	  where	  prM	  is	  cleaved	  by	  furin	  into	  pr	  (N-­‐terminal	  half,	  bound	  to	  sE)	  and	  M	  (membrane-­‐anchored	  C-­‐terminal	  half).	  Upon	  reaching	  the	  external	  milieu,	  sE	  and	  pr	  dissociate,	  and	  the	  sE	  component	  is	  purfied	   by	   affinity	   chromatography	   from	   the	   cells’	   supernatant	   fluid.	   Clarified	   cell	  supernatants	  were	   concentrated	   20-­‐fold	   using	   Vivaflow	   tangential	   filtration	   cassettes	  (Sartorius,	  cut-­‐off	  10	  kDa)	  and	  adjusted	  to	  pH	  8.0,	  Tris	  20mM	  and	  500mM	  NaCl	  before	  purification	   in	   an	   AKTA	   FPLC	   system	   by	   HisTrap-­‐HP	   chromatography	   after	   buffer	  exchange	   to	   remove	   chelating	   agents	   from	   the	   culture	   medium.	   The	   protein	   was	  desalted	   after	   elution	   of	   the	   HisTrap	   column	   and	   further	   purified	   by	   ion	   exchange	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chromatography	  on	  MonoQ.	  	  A	  final	  purification	  gel	  filtration	  step	  using	  a	  Superdex	  200	  10/300	  GL	  column	  equilibrated	  in	  50mM	  Tris	  pH8,	  500mM	  NaCl.	  
Note	   that	   the	   last	   4	   residues	   (392-­‐395)	   were	   inadvertently	   replaced	   by	   a	   “vector”	  sequence	  “LRPL”	  instead	  of	  “FKKG”	  as	  in	  the	  correct	  DENV-­‐2	  sequence	  (see	  ED	  Fig.	  4a).	  Fortunately,	  the	  “vector”	  residues	  correctly	  completed	  the	  β-­‐strand	  G	  of	  domain	  III	  and	  did	  not	   introduce	  any	  detectable	  difference	   in	  conformation	  there	  as	  compared	  to	   the	  other	  available	  structures	  of	  DENV-­‐2	  sE.	  This	  discrepancy	   in	   the	  amino	  acid	  sequence	  has	  been	  explicitly	  indicated	  in	  the	  deposited	  PDB	  file.	  
Production	  of	  antigen-­‐binding	  (Fab)	  and	  single-­‐chain	  Fv	  (scFv)	  fragments	  of	  the	  
bnAbs	  
The	   bnAb	   fragments	   were	   cloned	   into	   plasmids	   for	   expression	   as	   Fab34	   and	  scFv35	   in	  Drosophila	   S2	   cells.	   The	   constructs	   contain	   a	   twin	   strep	   tag	   fused	   at	   the	   C-­‐terminus	   (only	  of	   the	  heavy	  chain	   in	   the	  case	  of	   the	  Fab)	   for	  affinity	  purification.	  The	  purification	   protocol	   included	   streptactin	   affinity	   column	   followed	  by	   gel	   filtration	   as	  described	  above.	  
Immune	  complex	  formation	  and	  isolation.	  
The	  purified	  DENV-­‐2	  sE	  protein	  was	  mixed	  with	  Fabs	  or	  ScFvs	  (in	  ~2-­‐fold	  molar	  excess)	  in	  standard	  buffer	  (500mM	  NaCl,	  Tris	  50mM	  pH	  8.0).	  The	  volume	  was	  brought	  to	  0.2ml	  by	  centrifugation	  in	  a	  Vivaspin	  10kDa	  cutoff,	  after	  30	  min	  incubation	  at	  4°C,	  the	  complex	   was	   separated	   from	   excess	   Fab	   or	   scFv	   by	   size	   exclusion	   chromatography	  except	  when	  a	  clear	  peak	  for	  the	  complex	  was	  not	  obtained.	  In	  this	  case,	  a	  molar	  ratio	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1:2	   antigen:antibody	  mixture	   (i.e.,	   with	   an	   excess	   of	   antibody)	   was	   directly	   used	   for	  crystallization.	  In	  all	  cases,	  the	  buffer	  was	  exchanged	  to	  150mM	  NaCl,	  15mM	  Tris,	  pH	  8	  for	  crystallization	  trials.	  The	  protein	  concentrations	  used	  for	  crystallization,	  determined	  by	   measuring	   the	   optical	   density	   at	   280	   nm	   and	   using	   an	   extinction	   coefficient	  estimated	  from	  the	  amino	  acid	  sequences,	  are	  listed	  in	  ED	  Table	  1.	  
Crystallization	  and	  3D	  structure	  determinations.	  
Crystallization	   trials	   were	   carried	   out	   in	   sitting	   drops	   of	   400nl.	   Drops	   were	  formed	  by	  mixing	  equal	  volumes	  of	  the	  protein	  and	  reservoir	  solution	  in	  the	  format	  of	  96	  Greiner	  plates,	   using	   a	  Mosquito	   robot,	   and	  monitored	  by	   a	  Rock-­‐Imager.	   Crystals	  were	   optimized	  with	   a	   robotized	  Matrix	  Maker	   and	  Mosquito	   setups	   on	  400nl	   sitting	  drops,	  or	  manually	  in	  24	  well	  plates	  using	  2-­‐3µl	  hanging	  drops.	  The	  crystallization	  and	  cryo-­‐cooling	  conditions	  for	  diffraction	  data	  collection	  are	  listed	  in	  ED	  Table	  1.	  
X-­‐ray	  diffraction	  data	  were	  collected	  at	  beam	  lines	  PROXIMA-­‐1	  and	  PROXIMA-­‐2	  at	   the	   SOLEIL	   synchrotron	   (St	   Aubin,	   France),	   and	   ID23-­‐2	   and	   ID29	   at	   the	   European	  Synchrotron	  Radiation	  Facility	   (Grenoble,	  France)	   (ED	  Table	  1).	  Diffraction	  data	  were	  processed	  using	  the	  XDS	  package36	  and	  scaled	  with	  SCALA	  or	  AIMLESS37	  in	  conjunction	  with	  other	  programs	  of	  the	  CCP4	  suite38.	  The	  structures	  were	  determined	  by	  molecular	  replacement	   with	   PHASER39	   and	   /	   or	   AMoRe40	   using	   the	   search	  models	   listed	   in	   ED	  Table	  1.	  
Subsequently,	   careful	   model	   building	   with	   COOT41,	   alternating	   with	   cycles	   of	  crystallographic	   refinement	   with	   program	   BUSTER/TNT42,	   led	   to	   a	   final	   model.	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Refinement	  was	  constrained	   to	   respect	  non	  crystallographic	   symmetry,	   and	  also	  used	  target	   restraints	   (with	   high	   resolution	   structures	   of	   parts	   of	   the	   complexes)	   and	   TLS	  refinement43	   depending	   on	   the	   resolution	   of	   the	   crystal	   (see	   ED	   Table	   1).	   Final	   omit	  maps	  were	  calculated	  using	  Phenix.Refine44	  (ED	  Fig.	  7).	  
Analysis	  of	  the	  atomic	  models	  and	  Illustrations.	  
Each	   complex	   was	   analyzed	   with	   the	   CCP4	   suite	   of	   programs38.	   For	   inter-­‐molecular	  interactions,	  the	  maximal	  cutoff	  distance	  used	  for	  the	  interactions	  was	  4.75Å.	  Then	  the	  contacts	  of	  each	  residue	  of	  the	  Fab/ScFv	  or	  of	  DENV	  sE	  proteins	  were	  counted	  and	  plotted	  as	  a	  proportional	  bar	  above	  the	  corresponding	  residue.	  
	  The	  Ab	  sequences	  were	  analyzed	  by	  Abysis	   (www.bioinf.org.uk/software)	  and	  IMGT	  (www.imgt.org)33	  websites	   for	  mapping	  CDR/FWR	  regions	  according	  to	  Kabat32	  and	  IMGT33	  conventions,	  respectively.	  The	  analysis	  of	  the	  putative	  germline	  and	  somatic	  maturation	  events	  was	  done	  with	  the	  IMGT	  website	  (www.imgt.org).	  
Multiple	   sequence	   alignments	   were	   calculated	   using	   ClustalW	   (ClustalW	   and	  ClustalX	   version	   2	   (ref.	   45)	   on	   the	   EBI	   server46.	   The	   Figures	   were	   prepared	   using	  Program	   ESPript47	   and	   the	   PyMOL	   Molecular	   Graphics	   System,	   Version	   1.5.0.4	  Schrödinger,	   LLC.	   (pymol.sourceforge.net)	   with	   APBS48	   and	   PDB2PQR	   tools49.	   For	  analysis	  purposes,	  we	  created	  an	  atomic	  model	  for	  the	  DENV-­‐2	  sE	  dimer	  based	  on	  chain	  A	  of	  sE	  from	  the	  complex	  with	  B7	  (PDB	  4UT6),	  which	  had	  no	  density	  breaks,	  in	  order	  to	  calculate	   the	   corresponding	   surface	   of	   the	   sE	   dimer	   presented	   in	   the	   corresponding	  panels	  in	  Figs	  2b,	  3	  and	  ED	  Fig.	  2.	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Table 1. Germline analysis of bnAbs EDE1 and EDE2. 
 
Heavy  V-H allele V-H  V-H aa J-H allele D-H allele        CDR length BSA (%) 
chain  diverg|| ch/tot¶    [1:2:3] CDR[1:2:3] [CDR:FWR] 






         






         
EDE1 C8 IGHV3-64D*06 6.94%  12/98 IGHJ6*02 IGHD2-21*01 [8:8:15]§ [0:14:23]§  [37:24]§ 
      [5:17:13]# [0:22:23]# [45:16]# 
         






         
Light  V-L allele V-L  V-L aa J-L allele CDR length BSA (%) 
chain  diverg|| ch/tot¶    [1:2:3] CDR[1:2:3] [CDR:FWR] 






         






         






         






V-H, J-H, D-H, V-L, J-L represent the putative Homsap genes and alleles corresponding to the given bnAb, predicted by IMGT 
analysis (see methods).  
†: Additional possibilities were also predicted by IMGT (not shown). 
||: Nucleotide (nt) divergence (diverg). The total length for all V-H and V-L alleles is 288nt except for EDE1 C8 V-L (279nt). 
¶: Number of amino acid (aa) changes out of total V-H/V-L aa length (ch/tot). 
BSA (buried surface area) for CDR and FRW regions. BSA per CDR or FRW regions are shown as percentage of the total BSA of 
Fab or ScFv within the complex with DENV-2 sE. BSA are represented per individual H-CDRs [1:2:3] and L-CDRs [1:2:3] or as a 
sum for light/heavy chain CDRs and FWRs [CDR:FWR]. 







       
Crystal  DENV-2 sE  
EDE2 A11 
ScFv fragment 
DENV-2 sE /  
EDE2 B7 
Fab fragment 
DENV-2 sE /  
EDE2 A11 
Fab fragment 
DENV-2 sE /  
EDE1 C8 
Fab fragment 




PDB ID 4UTC 4UT7 4UT6 4UTB 4UTA 4UT9 
Maximum resolution (Å) 3.1 1.7 3.2 3.85 3.0 3.2 
Crystallization conditions 













Crystallization buffer  100mM Tris pH 8.0 
86 mM NaFormate 
16% PEG 3,350 
100mM MES pH 6.5 
25% (v/v) PEG MME550 
10mM ZnSO4 
100mM Tris pH 8.5 
16% (w/v) PEG 400 
200mM MgCl2 
100mM Hepes pH 7.5 
10% (w/v) PEG 6,000 
5% (v/v) MPD 
100mM Tris pH 8.5 
18% (w/v) PEG 8,000 
200mM Li2SO4 
100mM HEPES pH7.5 
20% (w/v) PEG 8,000 
Cryo-protectant solution 100 mM NaFormate 
18% PEG 3,350 
15% glycerol 
10% PEG 400 
No additional 
cryoprotectant 
22% Glycerol in 67% of 
crystallization solution 
 
Mix of Paratone-N 
with Paraffin Oil (1:1) 
22% Glycerol in 67% of 
crystallization solution 
22% PEG 400 in 67% of 
crystallization solution 















Space group  P 43 21 2 C 2 P 2 P 21 21 21 P 21 21 21 P 1 
Unit cell   a, b, c (Å) 
                α, β, γ (°) 
105.4, 105.4, 165.8 
90, 90, 90 
62.9, 47.7, 90.7 
90, 102.4, 90 
101.3, 59, 191.6 
90, 96.2, 90 
58.8, 181.9, 204.8 
90, 90, 90 
59.6, 191.3, 203.6 
90, 90, 90 
57.5, 102.2, 131.1 
91.5, 85.7, 96.1 
Resolution (Å) 30-3.1 (3.26-3.1) 30-1.7 (1.73-1.7) 30-3.2 (3.34-3.2) 30-3.85 (4.22-3.85) 30-3.0 (3.11-3.0) 30-3.2 (3.3-3.2) 
Measured reflections 301113 (15609) 91989 (2744) 136737 (16536) 102269 (22119) 204824 (20833) 89842 (8410) 
Unique reflections 17615 (2395) 28835 (1467) 37500 (4534) 21168 (4997) 45639 (4492) 46477 (4332) 
Completeness (%) 99.3 (96.0) 99.3 (95.5) 99.3 (99) 98.3 (98.3) 96.2 (97.6) 95.2 (96.7) 
Mn(I) half-set correlation  ND 0.996 (0.811) 0.993 (0.716) 0.981 (0.727) 0.993 (0.560) 0.977 (0.541) 
<I / σI> 23.9 (2.5) 8.9 (1.6) 9.2 (1.6) 5.8 (1.4) 7.9 (1.2) 5.0 (1.2) 
Rmerge (%) 9.7 (60.9) 7.2 (43.6) 10.9 (64.0) 27.1 (92.5) 12.9 (101.1) 18.7 (55.5) 
Structure Determination 




DENV-2 sE / 
bnAb EDE2 A11 Fab 
 
DENV-2 sE / 
bnAb EDE2 A11 Fab 
 
3KDM, 3H0T, 1OKE 
 





NCS 2 None 2 2 2 4 
Targeting 1OAN None None 3H0T, 3TJE, DENV-2 sE, 
bnAb EDE2 A11 ScFv, 
DENV-2 sE / bnAb EDE2 B7 Fab 
3KDM, 3EYF,  
DENV-2 sE, 1OAN 
1OAN 
 
Use of TLS No Yes Yes No No Yes 
Refinement‡ 
Rcryst. (%) / Rfree (%) 
 
21.1 / 27.9 
 
16.0 / 19.1 
 
21.2 / 25.0 
 
23.0 / 25.7 
 
21.35 / 24.9 
 
20.0 / 24.9 
N° of Work/Test reflections 17453 / 882 28441 / 1428 37165 / 1984 21007 / 1070 45462 / 2306 46344 / 2343 
N° of protein atoms 6072 2007 9681 12518 12496 19085 
N° of heteroatoms 177 214 222 200 252 56 
Rms deviation from ideal       
  Bond lengths (Å)  0.010 0.010 0.008 0.008 0.010 0.008 
  Bond angles (°) 1.33 1.03 1.13 1.18 1.28 1.10 
Ramachandran plot§       
  Favoured (%) 92.1 98.0 91.3 96.1 94.9 91.5 
  Allowed (%) 6.7 2.0 7.0 3.8 4.8 7.2 




Fab or ScFv BSA DENV-2 sE Complex 
 vH vL Total Reference subunit (glycans*) 
Opposite subunit 
(glycans*) Total (Å




molecule (Å2) SC 
 
DENV-2 sE / EDE2 B7 
Epitope A 992.1 180.8 1172.9 621.1 (83.6) 478.4 (358.0) 1099.5  233 (21.2%) 442 (40%) 1136.2 0.728 
Epitope B 1010.4 181.5 1191.9 501.8 (358.0) 604.1 (68.2) 1105.9  234 (21.2%) 426  (39%) 1148.9 0.721 
 
DENV-2 sE / EDE2 A11 
Epitope A 945.1 199.4 1144.5 544.2 (17.80) 491.9 (359.1) 1036.1  224 (21.6%) 377 (36%) 1090.3 0.706 
Epitope B 984.8 183.2 1168.0 473.4 (351.4) 587.5 (64.4) 1060.9 221 (20.8%) 416 (39%) 1114.5 0.668 
 
DENV-2 sE / EDE1 C8 
Epitope A 744.2 492.3 1236.5 944.9 (204.9) 234.6 1197.6 362 (30.2%) 204.9 (17%) 1217.1 0.693 
Epitope B 855.7 559.2 1414.9 366.4 963.3 (239.2) 1329.4 352 (26.5%) 239.2 (18%) 1372.2 0.687 
 
DENV-2 sE / EDE1 C10‡ 
Epitope A 706.6 623.3 1329.9 781.3 (84.5) 366.9 1148.2 351 (31%) 84.5 (7.3%) 1239.1 0.681 
Epitope B 706.0 644.4 1350.4 373.2 778.3 (94.20) 1151.5  320 (28%) 94.2 (8.2%) 1251.0 0.681 
Epitope C 823.7 562.6 1386.3 717.8 (90.6) 465.6 1183.4  374 (32%) 90.6 (7.6%) 1284.9 0.742 






MCSGKFSIDKEM TVVKVK AGAPCKVPIEIRDVNKEKVVGRIISSTPLAENTNSVTNIELEPPFGDSYIVI GNSALTLHWFRKG
MCLNTFVLKKEV ILIKVE EDAPCKIPFSTEDGQGKAHNGRLITANPVVTKKEEPVNIEAEPPFGESNIVI GDKALKINWYRKG


























WGNGCGLFGKGGVVTCAKFSCSGKITG VQI TVVVTVHN EGDT DTSNHGVTAMITPRSPSV VKLPDYGEL LDCEPRSGIDFNEMILMK
WGNGCGLFGKGSLVTCAKFQCLESIEG VQH TVIITVHTGDQ ET..QGVTAEITSQASTAEAILPEYGTL LECSPRTGLDFNEMILLT


















MRCVGVGNRDFVEGVSGGAWVDLVLEHGGCVTTMAQG TKTT EVALLRTYCIE NITTATRCPTQGEPYLKEEQDQQYICRRDVVDRGASIS
MRCVGVGNRDFVEGLSGATWVDVVLEHGGCVTTMAKN QKTE QLATLRKLCIE NITTDSRCPTQGEAILPEEQDQNYVCKHTYVDRGGKIT
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II. vL chains CDR L2CDR L1
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V
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CDR: H1 H2 H3 L1 L2 L3 FRW:














Recognition	  determinants	  of	  broadly	  neutralizing	  human	  
antibodies	  against	  dengue	  viruses	  
 
 
 Alexander	  Rouvinski1,2*,	  Pablo	  Guardado-­‐Calvo1,2*,	  Giovanna	  Barba-­‐Spaeth1,2*,	  Stéphane	  Duquerroy1,2,3,	  Marie-­‐Christine	  Vaney1,2,	  Carlos	  M.	  Kikuti1,2‡,	  M.	  Erika	  Navarro	  Sanchez1,2‡,	  Wanwisa	  Dejnirattisai4,	  Wiyada	  Wongwiwat4,	  Ahmed	  Haouz5,	  Christine	  Girard-­‐Blanc5,	  Stéphane	  Petres5,	  William	  E.	  Shepard6,	  Philippe	  Desprès7‡,	  Fernando	  Arenzana-­‐Seisdedos8,	  Philippe	  Dussart9‡,	  Juthathip	  Mongkolsapaya4,10§,	  Gavin	  R.	  Screaton4§	  and	  Félix	  A.	  Rey1,2,5§	  	  This	  file	  contains:	  	   Page	  Table	  of	  polar	  interactions	   2	  	  Histograms	  of	  antibody	  contacts	  per	  E	  protein	  residue:	   	   3	  a	   DENV-­‐2	  sE	  /	  EDE2	  A11	  complex	   4	  b	   	   /	  EDE2	  B7	  complex	   5	  c	   	   /	  EDE1	  C8	  complex	   6	  d	   	   /	  EDE1	  C10	  complex	   7-­‐8	  	   	   	   	  	  Histograms	  of	  E	  contacts	  per	  antibody	  residue:	   	  	  9	  a	   DENV-­‐2	  sE	  /	  EDE2	  A11	  complex	   10	  b	   	   /	  EDE2	  B7	  complex	   11	  c	   	   /	  EDE1	  C8	  complex	   12	  d	   	   /	  EDE1	  C10	  complex	   13-­‐14	  	   	   	  	  
	  
SI Table. Polar and salt bridges interactions between DENV sE and bnAb EDE1&2 Fab or ScFv.
epitope  sE dist B7 CDR sE dist C8 CDR sE dist C10 CDR
E71[OE2] 3.23 K95[NZ] L3 T68[O] 3.11 A57[N] H2 E71[OE2] 3.01 R94[NH1] L3
S72[N] 3.0 P100H[O] H3 T70[OG1] 2.96 S56[OG] H2 S72[N] 3.08 S93[O] L3
S72[OG] 2.86 D100I[OD1] H3 T70[N] 3.23 S56[OG] H2 S81[O] 3.49 R94[NH1] L3
T70[O] 2.76 W94[NE1] L3 E84[OE2] 3.99 E94[NH2] L3
S72[O] 3.48 N93[ND2] L3
Q77[NE2] 3.46 Y92[OH] L3
E84[OE1] 3.67 K64[NZ] H2
E84[OE2] 3.71 K64[NZ] H2
E71[OE1] 3.11 K95[NZ] L3 T68[O] 3.11 A57[N] H1 E71[OE2] 3.33 R94[NH1] L3
S72[N] 2.95 P100H[O] H3 T70[OG1] 3.10 S56[OG] H1 S72[N] 3.18 S93[O] L3
S72[OG] 3.30 P100H[O] H3 T70[N] 3.14 S56[OG] H1 E84[OE1] 3.76 R94[NH2] L3
S72[OG] 2.83 D100I[OD1] H3 T70[O] 2.80 W94[NE1] L3
E84[OE2] 3.94 K64[NZ] H2
E84[OE1] 3.83 K64[NZ] H2
72[N] 3.03 S93[O] L3
E84[OE1] 3.77 R94[NH2] L3
E71[OE2] 3.79 R94[NH1] L3
S72[N] 3.15 S93[O] L3
E84[OE1] 3.40 R94[NH2] L3
E84[OE2] 3.69 R94[NH2] L3
R99[NH2] 2.78 D100I[OD1] H3 R99[NH1] 3.10 N93[OD1] L3 G104[O] 2.78 N31[N] L1
R99[NH2] 2.80 D100I[OD2] H3 R99[NH2] 2.98 N93[OD1] L3
G102[O] 3.08 S100C[N] H3 G104[O] 2.86 N93[N] L3
G102[O] 2.90 S100C[OG] H3
R99[NH2] 2.80 D100I[OD1] H3 R99[NH1] 2.96 N93[OD1] L3 G104[O] 2.80 N31[N] L1
R99[NH2] 2.81 D100I[OD2] H3 R99[NH2] 2.89 N93[OD1] L3
G102[O] 2.98 S100C[N] H3 G104[O] 2.93 N93[N] L3
G102[O] 2.71 S100C[OG] H3
C G104[O] 3.00 N31[N] L1
D G104[O] 2.85 N31[N] L1
K246[O] 2.87 Y100G[OH] H3 K247[NZ] 3.84 E53[OE1] H2
K247[NZ] 3.63 D55[OD2] H2 K247[NZ] 2.75 D55[OD2] H2
Q248[O] 3.36 Y100F[OH] H3 Q248[N] 3.03 Y100[OH] H3
K246[O] 2.67 Y100G[OH] H3 K247[NZ] 2.78 D55[OD2] H2
K247[NZ] 3.65 D53[OD2] H2 Q248[O] 3.50 Y100[OH] H3
Q248[O] 3.29 Y100F[OH] H3 Q248[N] 2.97 Y100[OH] H3
C
D
N67-1[O6] 3.21 M68[SD] FH3 N67-1[O3] 3.0 G65[O] H2
N67-4[O2] 2.70 S82B[OG] FH3
N67-1[O3] 3.0 G65[O] H2
N67-4[O2] 3.32 S82B[OG] FH3
C
D N67-1[O5] 3.34 Q64[NE2] H2
R2[NH2] 3.27 D99[OD1] H3
R2[NH2] 3.19 R99[OD2] H3
E44[OE2] 3.34 Y100[OH] H3
R2[NH2] 3.53 D99[OD1] H3
R2[NH2] 3.64 D99[OD2] H3
E44[OE2] 3.37 Y100[OH] H3
R2[NH2] 3.07 D99[OD2] H3
E44[OE1] 2.73 Y100[OH] H3
R2[NH2] 3.20 D99[OD1] H3
R2[NH2] 3.11 D99[OD2] H3
E44[OE2] 2.70 Y100[OH] H3
L45[O] 3.49 Y100[OH] H3
D154[N]  3.07 S100C[OG] H3
T155[OG1] 2.86 Y99[OH] H3
T155[OG1] 3.03 S100C[O] H3
T155[OG1] 3.35 S31[OG] H1
G152[O] 3.50 S100C[OG] H3
T155[OG1] 3.11 S31[OG] H1
T155[OG1] 2.87 Y99[OH] H3
T155[OG1] 2.89 S100C[O] H3
D154[N] 3.04 S100C[OG] H3
N153-1[N2] 3.0 Y99[O] H3
N153-4[O4] 3.20  S56[OG] L2
N153-4[O4] 3.0  S56[N] L2
N153-1[N2] 3.0 Y99[O] H3
N153-4[O4] 3.10  S56[OG] L2
N153-4[O4] 3.0  S56[N] L2




B  S274[N] 3.30 E53[OE2] H1
K310[NZ] 3.69 D50[OD1] L2 K310[NZ] 3.40 N31[OD1] L1
E311[OE1] 3.94 R66[NH1] FL3 K310[NZ] 3.49 D50[OD1] L2
E311[OE2] 2.74 R66[NH1] FL3 K310[NZ] 3.35 D50[OD2] L2
E311[OE2] 3.28 R66[NH2] FL3 R323[NH1] 3.01 S53[OG] L2
E311[OE1]  3.28  S30[OG] FL1 R323[NH1] 3.18 D50[OD1] L2
D362[OD2]  3.69 R54[NH1] L2 R323[NH2] 3.05 D50[OD1] L2
D362[O] 2.71 R54[NH2] L2
D362[OD2] 3.16 S60[OG] FL3
K310[NZ ] 3.62 D50[OD1] L2 K310[NZ] 3.60 D50[OD1] L2
K310[NZ] 3.23 D50[OD2] L2
E311[OE1] 3.35 R66[NH1] FL3 K310[NZ] 2.89 N31[OD1] L1
E311[OE1] 3.65 R66[NH2] FL3 R323[NH1] 3.19 D50[OD1] L2
E311[OE2] 2.80 R66[NH1] FL3 R323[NH2] 3.67 D50[OD1] L2
R323[NH1] 3.28 S53[OG] L2
D362[O] 3.02 R54[NH2] L2
K310[NZ] 3.33  D50[OD2] L2
K310[NZ] 3.33  D50[OD1] L2
 R323[NH1] 2.89  S53[OG] L2
 R323[NH1] 3.41  D50[OD1] L2
 R323[NH2] 2.99  D50[OD1] L2
 D362[O] 3.04 R54[NH2] L2
K310[NZ] 3.47  D50[OD2] L2
K310[NZ] 3.12  D50[OD1] L2
 R323[NH1] 3.77  D50[OD1] L2
 D362[O] 3.36 R54[NH2] L2
In black: Hydrogen bonds (d ≤ 3.5 Å). In bold black and yellow background : Salt bridges (d ≤ 4 Å).
In bold red: Main chain atoms involved in contacts. In bold blue: Sugar atoms involved in contacts.
In grey background: the epitopes C and D do not exist in the corresponding stuctures. Distances(dist) are reported in Å. 



































































































Histograms	  of	  antibody	  contacts	  per	  E	  protein	  residue:	  
The	   following	   pages	   display	   the	   number	   of	   contacts	   per	   sE	   residue	   along	   its	  amino	   acid	   sequence,	   as	   observed	   in	   the	   crystal	   structures	   of	   all	   of	   the	   independent	  complexes	  in	  the	  unit	  cells	  of	  the	  crystals	  analyzed	  in	  the	  paper,	  as	  indicated.	  	  







Histograms	  of	  E	  contacts	  per	  antibody	  residue:	  
The	  following	  pages	  mirror	  the	  diagrams	  displayed	  above,	  this	  time	  showing	  the	  number	  of	  contacts	  per	  antibody	  residue	  along	  the	  amino	  acid	  sequence	  of	  the	  bnAbs.	  
	  In	   each	   page,	   Part	   I	   shows	   the	   bnAb	   variable	   domain	   extracted	   from	   the	  corresponding	   complex,	   colored	   grey	   (VH	   dark	   grey,	   VL	   light	   grey)	   with	   somatic	  mutations	   in	   red	   and	   junction	   residues	   arising	   from	   recombination	   in	   green.	   	   Side	  chains	  involved	  in	  contacts	  are	  displayed	  in	  ball	  and	  stick	  and	  labeled.	  Part	  II	  shows	  the	  histogram	  of	   the	  number	  of	  atomic	  contacts	  per	  residue,	  color-­‐coded	  according	   to	   the	  key	   to	   indicate	   the	   region	   of	   sE	   that	   is	   contacted	   (in	   parenthesis,	   the	   symbol	   used	   in	  	  	  	  ED	   Fig.	   4b	   to	   mark	   the	   corresponding	   contact).	   The	   sequence	   numbering	   and	   the	  background	   corresponds	   to	   Kabat	   convention	   (as	   in	   ED	   Fig.	   4b).	   The	   CDRs	  corresponding	  to	  the	  IMGT	  convention	  are	  displayed	  as	  dotted	  orange	  lines	  above	  the	  sequences.	   Somatic	   mutations	   are	   in	   red,	   residues	   arising	   from	   VDJ	   (or	   VJ)	  recombination	  are	  in	  green.	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